Top

Published in:

Open Access 01-12-2020 | Breast Cancer

Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry

Authors: Anouk K. M. Claessens, Bram L. T. Ramaekers, Dorien J. A. Lobbezoo, Roel J. W. van Kampen, Maaike de Boer, Agnes J. van de Wouw, M. Wouter Dercksen, Sandra M. E. Geurts, Manuela A. Joore, Vivianne C. G. Tjan-Heijnen

Published in: Quality of Life Research | Issue 12/2020

Abstract

Purpose

We aimed to evaluate quality of life (QoL) using the European Quality of Life Five-Dimensions questionnaire (EQ-5D-3L) in a real-world cohort of Dutch advanced breast cancer (ABC) patients. Secondary, we reported differences in QoL between subgroups of patients based on age, comorbidity, tumor-, and treatment characteristics, and assessed the association of duration of metastatic disease and time to death with QoL.

Methods

ABC patients who attended the outpatient clinic between October 2010 and May 2011 were asked to fill out the EQ-5D-3L questionnaire. Patient-, disease-, and treatment characteristics were obtained from the medical files. Health-utility scores were calculated. Subgroups were described and compared for utility scores by parametric and non-parametric methods.

Results

A total of 92 patients were included with a median utility score of 0.691 (Interquartile range [IQR] 0.244). Patients ≥ 65 years had significantly worse median utility scores than younger patients; 0.638 versus 0.743, respectively (p = 0.017). Moreover, scores were significantly worse for patients with versus those without comorbidity (medians 0.620 versus 0.725, p = 0.005). Utility scores did not significantly differ between subgroups of tumor type, type of systemic treatment, number of previous palliative treatment(s), or number or location of metastatic site(s). The remaining survival was correlated with utility scores (correlation coefficient (r) = 0.260, p = 0.0252), especially in the subgroup < 65 years (r = 0.340, p = 0.0169), whereas there was no significant correlation with time since metastatic diagnosis (r = − 0.106, p = 0.3136).

Conclusion

Within this real-world cross-sectional study, QoL was significantly associated with age, comorbidity, and remaining survival duration. The observation of a lower QoL in ABC patients, possibly indicating the last period of life, may assist clinical decision-making on timing of cessation of systemic antitumor therapy.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492.CrossRef

Ruiterkamp, J., Ernst, M. F., de Munck, L., van der Heiden-van der Loo, M., Bastiaannet, E., van de Poll-Franse, L. V., et al. (2011). Improved survival of patients with primary distant metastatic breast cancer in the period of 1995–2008 A nationwide population-based study in the Netherlands. Breast Cancer Research and Treatment, 128(2), 495–501.CrossRef

Noone, A., Howlader, N., Krapcho, M., Miller, D., Brest, A., Yu, M., et al. (2018). SEER Cancer Statistics Review 1975 - 2015. based on November 2017 SEER data submission, posted to SEER webiste April 18. Bethesda, MD: National Cancer Insitute.

Cardoso, F., Spence, D., Mertz, S., Corneliussen-James, D., Sabelko, K., Gralow, J., et al. (2018). Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015). The Breast, 39, 131–138. https://doi.org/10.1016/j.breast.2018.03.002.CrossRefPubMed

Kramer, J. A., Curran, D., Piccart, M., de Haes, J. C., Bruning, P., Klijn, J., et al. (2000). Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. European Journal of Cancer, 36(12), 1498–1506.CrossRef

Efficace, F., Biganzoli, L., Piccart, M., Coens, C., Van Steen, K., Cufer, T., et al. (2004). Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. European Journal of Cancer, 40(7), 1021–1030. https://doi.org/10.1016/j.ejca.2004.01.014.CrossRefPubMed

Quinten, C., Coens, C., Mauer, M., Comte, S., Sprangers, M. A., Cleeland, C., et al. (2009). Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. The lancet Oncology, 10(9), 865–871. https://doi.org/10.1016/s1470-2045(09)70200-1.CrossRefPubMed

Montazeri, A. (2008). Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res, 29, 27–32. https://doi.org/10.1186/1756-9966-27-32.CrossRef

Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the Economical Evaluation of Health Care Programmes (4thth Edition ed.). Oxford: Oxford University Press.

10.

EuroQolGroupHomepage. Retrieved July 2, 2019, from https://euroqol.org/.

11.

Longworth, L., Yang, Y., Young, T., Mulhern, B., Hernandez Alava, M., Mukuria, C., et al. (2014). Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: A systematic review, statistical modelling and survey. Health Technology Assessment, 18(9), 1–224. https://doi.org/10.3310/hta18090.CrossRefPubMed

12.

Kennedy-Martin, M., Slaap, B., Herdman, M., van Reenen, M., Kennedy-Martin, T., Greiner, W., et al. (2020). Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. The European Journal of Health Economics. https://doi.org/10.1007/s10198-020-01195-8.CrossRefPubMedPubMedCentral

13.

EQ-5D-3L User Guide. (2018). Retrieved July 02, 2019, from https://euroqol.org/publications/user-guides/.

14.

Bottomley, A., & Therasse, P. (2002). Quality of life in patients undergoing systemic therapy for advanced breast cancer. The Lancet Oncology, 3(10), 620–628.CrossRef

15.

Ghislain, I., Zikos, E., Coens, C., Quinten, C., Balta, V., Tryfonidis, K., et al. (2016). Health-related quality of life in locally advanced and metastatic breast cancer: Methodological and clinical issues in randomised controlled trials. The Lancet Oncology, 17(7), e294–e304. https://doi.org/10.1016/S1470-2045(16)30099-7.CrossRefPubMed

16.

Hao, Y., Wolfram, V., & Cook, J. (2016). A structured review of health utility measures and elicitation in advanced/metastatic breast cancer. ClinicoEconomics and Outcomes Research, 23(8), 293–303. https://doi.org/10.2147/CEOR.S100448.CrossRef

17.

Adamowicz, K., Jassem, J., Katz, A., & Saad, E. D. (2012). Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. Cancer Treatment Reviews, 38(5), 554–558.CrossRef

18.

Brooks, R. G., Rabin, R., & De Charro, F. (2010). The measurement and valuation of health status using EQ-5D: A European perspective: Evidence from the EuroQol BIOMED Research Programme. Dordrecht: Kluwer Academic Publishers.

19.

Rautalin, M., Farkkila, N., Sintonen, H., Saarto, T., Taari, K., Jahkola, T., et al. (2018). Health-related quality of life in different states of breast cancer - comparing different instruments. Acta Oncologica, 57(5), 622–628. https://doi.org/10.1080/0284186X.2017.1400683.CrossRefPubMed

20.

ACTIONStudyGroup. (2017). Health-related quality of life and psychological distress among cancer survivors in Southeast Asia: Results from a longitudinal study in eight low- and middle-income countries. BMC Medicine, 15(1), 10. https://doi.org/10.1186/s12916-016-0768-2.CrossRef

21.

Wood, R., Mitra, D., de Courcy, J., & Iyer, S. (2017). Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR(+)/HER2(-) Advanced/Metastatic Breast Cancer. Clinical Therapeutics, 39(8), 1719–1728. https://doi.org/10.1016/j.clinthera.2017.07.009.CrossRefPubMed

22.

Wood, R., Mitra, D., de Courcy, J., & Iyer, S. (2017). Patient-reported pain severity, pain interference and health status in HR+/HER2− advanced/metastatic breast cancer. ESMO Open, 2(3), e000227. https://doi.org/10.1136/esmoopen-2017-000227.CrossRefPubMedPubMedCentral

23.

Walker, M. S., Hasan, M., Yim, Y. M., Yu, E., Stepanski, E. J., & Schwartzberg, L. S. (2011). Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients. Health and Quality of Life Outcomes. https://doi.org/10.1186/1477-7525-9-46.CrossRefPubMedPubMedCentral

24.

Guerra, R. L., Dos Reis, N. B., Correa, F. M., Fernandes, M. M., Ribeiro Alves Fernandes, R., Cancela, M. C., et al. (2019). Breast cancer quality of life and health-state utility at a Brazilian Reference Public Cancer Center. Expert Review of Pharmacoeconomics and Outcomes Research. https://doi.org/10.1080/14737167.2019.1621752.CrossRefPubMed

25.

McClelland, S. I., Holland, K. J., & Griggs, J. J. (2015). Quality of life and metastatic breast cancer: The role of body image, disease site, and time since diagnosis. Quality of Life Research, 24(12), 2939–2943. https://doi.org/10.1007/s11136-015-1034-3.CrossRefPubMed

26.

Lambert-Obry, V., Gouault-Laliberte, A., Castonguay, A., Zanotti, G., Tran, T., Mates, M., et al. (2018). Real-world patient- and caregiver-reported outcomes in advanced breast cancer. Current Oncology, 25(4), e282–e290. https://doi.org/10.3747/co.25.3765.CrossRefPubMedPubMedCentral

27.

Müller, V., Nabieva, N., Haberle, L., Taran, F. A., Hartkopf, A. D., Volz, B., et al. (2018). Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast, 37, 154–160. https://doi.org/10.1016/j.breast.2017.08.008.CrossRefPubMed

28.

Oh, S., Heflin, L., Meyerowitz, B. E., Desmond, K. A., Rowland, J. H., & Ganz, P. A. (2004). Quality of life of breast cancer survivors after a recurrence: A follow-up study. Breast Cancer Research and Treatment, 87(1), 45–57. https://doi.org/10.1023/B:BREA.0000041580.55817.5a.CrossRefPubMed

29.

Mangen, M. J., Bolkenbaas, M., Huijts, S. M., van Werkhoven, C. H., Bonten, M. J., & de Wit, G. A. (2017). Quality of life in community-dwelling Dutch elderly measured by EQ-5D-3L. Health and Quality of Life Outcomes. https://doi.org/10.1186/s12955-016-0577-5.CrossRefPubMedPubMedCentral

30.

Nolte, S., Liegl, G., Petersen, M. A., Aaronson, N. K., Costantini, A., Fayers, P. M., et al. (2019). General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. European Journal of Cancer, 107, 153–163. https://doi.org/10.1016/j.ejca.2018.11.024.CrossRefPubMed

31.

Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.CrossRef

32.

Brooks, R. (1996). EuroQol: the current state of play. Health Policy, 37(1), 53–72.CrossRef

33.

EuroQolGroup. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef

34.

Marra, C. A., Woolcott Jc Fau - Kopec, J. A., Kopec Ja Fau - Shojania, K., Shojania K Fau - Offer, R., Offer R Fau - Brazier, J. E., Brazier Je Fau - Esdaile, J. M., et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. (0277–9536 (Print)).

35.

Cohen, J., Cohen, P., West, S. G., & Aiken, L. S. (2003). Applied multiple regression/correlation analysis for the behavioral sciences. New York: Routlegde.

36.

Dranitsaris, G., Beegle, N., Kalberer, T., Blau, S., Cox, D., & Faria, C. (2015). A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting. Journal of Oncology Pharmacy Practice, 21(3), 170–177. https://doi.org/10.1177/1078155214525369.CrossRefPubMed

37.

Xie, J., Hao, Y., Li, N., Lin, P. L., Ohashi, E., Koo, V., et al. (2015). Clinical outcomes among HR+/HER2− metastatic breast cancer patients with multiple metastatic sites: A chart review study in the US. Experimental Hematology and Oncology, 12(4), 31. https://doi.org/10.1186/s40164-015-0023-0.CrossRef

38.

Pentheroudakis, G., Fountzilas, G., Bafaloukos, D., Koutsoukou, V., Pectasides, D., Skarlos, D., et al. (2006). Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Research and Treatment, 97(3), 237–244. https://doi.org/10.1007/s10549-005-9117-4.CrossRefPubMed

39.

Kurosky, S. K., Mitra, D., Zanotti, G., & Kaye, J. A. (2018). Treatment patterns and outcomes of patients with metastatic ER(+)/HER-2(−) breast cancer: A multicountry retrospective medical record review. Clinical Breast Cancer, 18(4), e529–e538. https://doi.org/10.1016/j.clbc.2017.10.008.CrossRefPubMed

40.

Cinausero, M., Gerratana, L., De Carlo, E., Iacono, D., Bonotto, M., Fanotto, V., et al. (2018). Determinants of last-line treatment in metastatic breast cancer. Clinical Breast Cancer, 18(3), 205–213. https://doi.org/10.1016/j.clbc.2017.07.008.CrossRefPubMed

41.

Galy, G., Labidi-Galy, S. I., Perol, D., Bachelot, T., Ray-Coquard, I., Tredan, O., et al. (2011). Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994–1998 and 2003–2006. Breast Cancer Research and Treatment, 128(1), 187–195.CrossRef

42.

Lidgren, M., Wilking, N., Jönsson, B., & Rehnberg, C. (2007). Health related quality of life in different states of breast cancer. Quality of Life Research, 16(6), 1073–1081. https://doi.org/10.1007/s11136-007-9202-8.CrossRefPubMed

43.

Kim, E. J., Ko, S. K., & Kang, H. Y. (2012). Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients. Quality of Life Research, 21(7), 1193–1203. https://doi.org/10.1007/s11136-011-0037-y.CrossRefPubMed

44.

Knies, S., Evers Sm Fau - Candel, M. J. J. M., Candel Mj Fau - Severens, J. L., Severens Jl Fau - Ament, A. J. H. A., & Ament, A. J. Utilities of the EQ-5D: transferable or not? (1170–7690 (Print)).

45.

Lamers, L. M., McDonnell, J., Stalmeier, P. F. M., Krabbe, P. F. M., & Busschbach, J. J. (2006). The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Economics, 15(10), 1121–1132. https://doi.org/10.1002/hec.1124.CrossRefPubMed

46.

Liu, L., Li, S., Wang, M., & Chen, G. (2017). Comparison of EQ-5D-5L health state utilities using four country-specific tariffs on a breast cancer patient sample in mainland China. Patient Prefer Adherence, 23(11), 1049–1056. https://doi.org/10.2147/PPA.S138028.CrossRef

47.

Karlsson, J. A., Nilsson, J. F., Neovius, M., Kristensen, L., Gulfe, A., Saxne, T., et al. (2011). National EQ-5D tariffs and quality-adjusted life-year estimation: Comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 70(12), 2163–2166. https://doi.org/10.1136/ard.2011.153437.CrossRefPubMed

48.

Zhao, Y., Li, S. P., Liu, L., Zhang, J. L., & Chen, G. (2017). Does the choice of tariff matter?: A comparison of EQ-5D-5L utility scores using Chinese, UK, and Japanese tariffs on patients with psoriasis vulgaris in Central South China. Medicine (Baltimore), 96(34), e7840. https://doi.org/10.1097/MD.0000000000007840.CrossRef

49.

Kiadaliri, A. A., Eliasson, B., & Gerdtham, U. G. (2015). Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients. Health and Quality of Life Outcomes, 15(13), 145. https://doi.org/10.1186/s12955-015-0344-z.CrossRef

50.

Mozzi, A., Meregaglia, M., Lazzaro, C., Tornatore, V., Belfiglio, M., & Fattore, G. (2016). A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample. ClinicoEconomics and Outcomes Research, 13(8), 267–274. https://doi.org/10.2147/CEOR.S98226.CrossRef

51.

Busschbach, J. J., Weijnen, T., Nieuwenhuizen, M., Oppe, S., Badia, X., Dolan, P., et al. (2003). A comparison of EQ-5D time trade-off values obtained in Germany, the United Kingdom and Spain. In R. Brooks, R. Rabin, & F. de Charro (Eds.), The measurement and valuation of health status using EQ-5D: A European perspective (pp. 143–165). Dordrecht: Kluwer Academic Publishers.CrossRef

52.

Badia, X., Roset, M., Herdman, M., & Kind, P. (2001). A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Medical Decision Making, 21(1), 7–16. https://doi.org/10.1177/0272989X0102100102.CrossRefPubMed

53.

Luo, N., Johnson, J. A., Shaw, J. W., & Coons, S. J. (2007). A comparison of EQ-5D index scores derived from the US and UK population-based scoring functions. Medical Decision Making, 27(3), 321–326. https://doi.org/10.1177/0272989X07300603.CrossRef

54.

Szende, A., Oppe, M., & Devlin, N. (2007). EQ-5D value sets: Inventory, comparative review and user guide. Dordrecht: Springer.CrossRef

55.

Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., Andre, F., et al. (2018). 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology, 29(8), 1634–1657. https://doi.org/10.1093/annonc/mdy192.CrossRefPubMed

56.

Efficace, F., Rees, J., Fayers, P., Pusic, A., Taphoorn, M., Greimel, E., et al. (2014). Overcoming barriers to the implementation of patient-reported outcomes in cancer clinical trials: the PROMOTION Registry. Health Quality and Life Outcomes, 12, 86. https://doi.org/10.1186/1477-7525-12-86.CrossRef

Title: Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry
Authors: Anouk K. M. Claessens
Bram L. T. Ramaekers
Dorien J. A. Lobbezoo
Roel J. W. van Kampen
Maaike de Boer
Agnes J. van de Wouw
M. Wouter Dercksen
Sandra M. E. Geurts
Manuela A. Joore
Vivianne C. G. Tjan-Heijnen
Publication date: 01-12-2020
Publisher: Springer International Publishing
Keywords: Breast Cancer
Breast Cancer
Published in: Quality of Life Research / Issue 12/2020
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-020-02604-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2020

Registered Reports: response from ISOQOL’s New Investigator SIG

Physical activity status in relation to quality of life and dietary habits in breast cancer survivors: subset analyses of KROG 14-09 nationwide questionnaire study

The importance of development standards for anchoring vignettes: an illustrative example from pediatric localized scleroderma quality of life

Registered reports and paediatric research

Patient-reported flare frequency is associated with diminished quality of life and family role functioning in systemic lupus erythematosus

EQ-5D-3L health status and health state utilities of the oldest-old (85 +) in Germany: results from the AgeCoDe-AgeQualiDe study